Antares Pharma (ATRS) Stock Forecast, Price & News

Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

Is Antares Pharma a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Antares Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRS, but not buy additional shares or sell existing shares.
View analyst ratings for Antares Pharma or view top-rated stocks.

Are investors shorting Antares Pharma?

Antares Pharma saw a increase in short interest in April. As of April 30th, there was short interest totaling 7,280,000 shares, an increase of 86.2% from the April 15th total of 3,910,000 shares. Based on an average daily volume of 4,320,000 shares, the days-to-cover ratio is currently 1.7 days. Approximately 4.4% of the shares of the company are sold short.
View Antares Pharma's Short Interest.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Antares Pharma.

How were Antares Pharma's earnings last quarter?

Antares Pharma, Inc. (NASDAQ:ATRS) announced its earnings results on Thursday, March, 3rd. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.01. The specialty pharmaceutical company earned $48.73 million during the quarter, compared to the consensus estimate of $46.25 million. Antares Pharma had a net margin of 21.90% and a trailing twelve-month return on equity of 7.43%. During the same period in the prior year, the business posted $0.03 EPS.
View Antares Pharma's earnings history.

What guidance has Antares Pharma issued on next quarter's earnings?

Antares Pharma issued an update on its FY 2022 earnings guidance on Thursday, March, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200 million-$220 million, compared to the consensus revenue estimate of $211.41 million.

What price target have analysts set for ATRS?

5 analysts have issued twelve-month price objectives for Antares Pharma's stock. Their forecasts range from $5.60 to $5.60. On average, they anticipate Antares Pharma's stock price to reach $5.60 in the next twelve months. This suggests a possible upside of 0.2% from the stock's current price.
View analysts' price targets for Antares Pharma or view top-rated stocks among Wall Street analysts.

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the following people:

• Mr. Robert F. Apple, CEO, Pres & Director (Age 56, Pay $1M)
• Mr. Fred M. Powell CPA, Exec. VP & CFO (Age 61, Pay $636.39k)
• Mr. Peter J. Graham Esq., Exec. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 55, Pay $634.48k)
• Mr. Patrick Madsen, Sr. VP of Operations
• Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 59)
• Ms. Tram Bui, VP of Corp. Communications & Investor Relations
• Mr. Edward Tykot, Sr. VP of Corp. Bus. Devel.
• Mr. Claude E. Richardson, Sr. VP of HR
• Dr. Peter Sadowski, Sr. VP of Technology Portfolio & Intellectual Property (Age 74)
• Dr. Jonathan S. Jaffe, Interim EVP, Pharmaceutical R&D and Chief Medical Officer

What is Paul K. Wotton's approval rating as Antares Pharma's CEO?

5 employees have rated Antares Pharma CEO Paul K. Wotton on Glassdoor.com. Paul K. Wotton has an approval rating of 18% among Antares Pharma's employees. This puts Paul K. Wotton in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Antares Pharma's key competitors?

Some companies that are related to Antares Pharma include West Pharmaceutical Services (WST), Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), ICU Medical (ICUI), Quidel (QDEL), Merit Medical Systems (MMSI), Haemonetics (HAE), Neogen (NEOG), STAAR Surgical (STAA), Meridian Bioscience (VIVO), Atrion (ATRI), Cerus (CERS), OraSure Technologies (OSUR) and Anika Therapeutics (ANIK).
View all of ATRS's competitors.

What other stocks do shareholders of Antares Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), (CGC), NVIDIA (NVDA), Conatus Pharmaceuticals (CNAT), Micron Technology (MU), Prospect Capital (PSEC), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE).

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.00%), Vanguard Group Inc. (5.06%), State Street Corp (2.02%), Russell Investments Group Ltd. (1.78%), First Wilshire Securities Management Inc. (1.64%) and Dimensional Fund Advisors LP (1.13%). Company insiders that own Antares Pharma stock include Anton Gueth, Fred M Powell, Leonard S Jacob, Peter J Graham, Robert F Apple and Thomas J Garrity.
View institutional ownership trends for Antares Pharma.

Which institutional investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, State Board of Administration of Florida Retirement System, Victory Capital Management Inc., BlackRock Inc., Northern Trust Corp, SG Americas Securities LLC, JPMorgan Chase & Co., and Invesco Ltd..
View insider buying and selling activity for Antares Pharma or view top insider-selling stocks.

Which institutional investors are buying Antares Pharma stock?

ATRS stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Velan Capital Investment Management LP, Assenagon Asset Management S.A., Dimensional Fund Advisors LP, Boston Partners, Renaissance Technologies LLC, Vanguard Group Inc., and State Street Corp.
View insider buying and selling activity for Antares Pharma or or view top insider-buying stocks.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $5.59.

How much money does Antares Pharma make?

Antares Pharma has a market capitalization of $955.06 million and generates $183.98 million in revenue each year. The specialty pharmaceutical company earns $46.29 million in net income (profit) each year or $0.239990 on an earnings per share basis.

How many employees does Antares Pharma have?

Antares Pharma employs 201 workers across the globe.

What is Antares Pharma's official website?

The official website for Antares Pharma is www.antarespharma.com.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at (609) 359-3020, via email at [email protected], or via fax at 302-655-5049.